BioXcel TherapeuticsBTAI -1.06%14 Days Payable is 4,989.41 as of Mar. 2026, which is 73% below its 10-year median of 18,806.10. GuruFocus rates BTAI with a GF Score™ of 14/100 and a GF Value™ of $0.67 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 921 Drug Manufacturers companies, BioXcel Therapeutics ranks better than 99.02% on this metric.
The historical rank and industry rank for BioXcel Therapeutics's Days Payable or its related term are showing as below:
BTAI'
s Days Payable Range Over the Past 10 Years
Min: 2524.51 Med: 18806.1 Max: 136017.25
Current: 13380.41
During the past 10 years, BioXcel Therapeutics's highest Days Payable was 136017.25. The lowest was 2524.51. And the median was 18806.10.
BTAI's Days Payable is ranked better than 99.02% of 921
companies
in the Drug Manufacturers industry
Industry Median: 90.69
vs BTAI: 13380.41
BioXcel Therapeutics's Days Payable
declined
from Mar. 2025 (102,460.71) to Mar. 2026 (4,989.41).
It may suggest that BioXcel Therapeuticsaccelerated paying its suppliers.
BioXcel Therapeutics Days Payable Related Terms
BioXcel Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for BioXcel Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioXcel Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioXcel Therapeutics Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioXcel Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where BioXcel Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BioXcel Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioXcel Therapeutics (BTAI) has a Days Payable of 4,989.41 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioXcel Therapeutics and its competitors. This is 73% below median its historical median of 18,806.10. Over the past decade, BioXcel Therapeutics' Days Payable has ranged from 2,524.51 to 136,017.25. According to the industry distribution chart, BioXcel Therapeutics ranks #9 out of 921 companies in the Drug Manufacturers industry, placing it in the top 1%.
Is BioXcel Therapeutics' Days Payable too high?
BioXcel Therapeutics' current Days Payable of 4,989.41 is 73% below median its 10-year median of 18,806.10. Over the past 10 years, this metric has ranged from a low of 2,524.51 to a high of 136,017.25. The Drug Manufacturers industry median Days Payable is 90.69. BioXcel Therapeutics' value of 4,989.41 is 5401.6% above this industry median. Based on the distribution chart, BioXcel Therapeutics ranks #9 out of 921 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioXcel Therapeutics has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioXcel Therapeutics' Days Payable compare to IXHL and SCYX?
According to the Drug Manufacturers industry distribution chart, BioXcel Therapeutics ranks #9 out of 921 companies for Days Payable. This places BioXcel Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.69. BioXcel Therapeutics' value of 4,989.41 is 5401.6% above this benchmark. Historically, BioXcel Therapeutics' own Days Payable has ranged from 2,524.51 to 136,017.25 over the past decade. While the company's 10-year median is 18,806.10 vs. the industry median of 90.69, BioXcel Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.69, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioXcel Therapeutics's current Days Payable of 4,989.41 is 5401.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioXcel Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioXcel Therapeutics's current Days Payable is 4,989.41, which is 73% below median its own 10-year median of 18,806.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (BTAI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.67, compared to a current price of $1.40 — trading 108.2% above its estimated fair value. The current Days Payable is 4,989.41, which is 73% below median its 10-year median of 18,806.10 and 5401.6% above the Drug Manufacturers industry median of 90.69. BioXcel Therapeutics' overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BioXcel Therapeutics (BTAI), the current Days Payable is 4,989.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioXcel Therapeutics (BTAI) Overvalued in 2026?
Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be overvalued.
The current stock price of $1.40 is trading 108.2% above its estimated GF Value™ of $0.67.
GuruFocus considers BioXcel Therapeutics to be Significantly Overvalued.
Key valuation signals for BTAI:
Days Payable: 4,989.41 (73% below median its 10-year median of 18,806.10)
GF Value™: $0.67 vs. price of $1.40 (108.2% above fair value)
Industry Position: 5401.6% above the Drug Manufacturers median (#9 of 921)
No single metric tells the full story. See the BTAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
14GF Score
Get the complete analysis for BTAI
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTAI has been successfully added to your 
